highperformr logo

Ascendis Pharma's Overview

Total employees1142
HeadquartersHellerup
Founded2007

Ascendis Pharma A/S is a dynamic, patient-focused biopharmaceutical company committed to improving patients' lives by developing innovative, best-in-class therapies. Utilizing its unique TransCon™ (Transient Conjugation) technology platform, Ascendis aims to create new treatments that offer enhanced efficacy, safety, and/or convenience. The company's primary focus areas include endocrinology rare diseases and oncology, with a growing pipeline of product candidates and marketed products. Ascendis Pharma is dedicated to scientific excellence and translating groundbreaking research into meaningful therapeutic solutions for unmet medical needs globally.

Where is Ascendis Pharma's Headquarters?

HQ Function

Serves as the global corporate headquarters, overseeing worldwide strategy, research and development leadership, finance, legal, and other core administrative functions. It's a key hub for innovation and global operations management.

Notable Features:

Modern office and laboratory facilities situated in the redeveloped Tuborg Havn (Tuborg Harbor) area, known for its contemporary architecture and waterfront views. The design likely emphasizes collaborative workspaces and state-of-the-art research infrastructure.

Work Culture:

Characterized by a strong emphasis on scientific innovation, patient-centricity, and collaboration. Employees often describe a fast-paced, dynamic environment driven by a shared mission to develop transformative therapies. The culture encourages teamwork, open communication, and a commitment to quality and ethical standards.

HQ Significance:

The Hellerup headquarters is central to Ascendis Pharma's identity and global strategy, anchoring its presence in the Medicon Valley, one of Europe's leading life science clusters. This location facilitates access to talent, research collaborations, and a supportive biotech ecosystem.

Values Reflected in HQ: The headquarters likely reflects values such as innovation (through its R&D facilities), collaboration (through its workspace design), and a forward-looking approach (modern architecture in a redeveloped area). Its location in Medicon Valley underscores a commitment to scientific excellence and community.

Location:

Ascendis Pharma operates globally with key functions distributed across its international sites. Research and development are primarily conducted in Denmark, Germany, and the United States (California). Clinical development, regulatory affairs, and medical affairs are strong in the U.S. (New Jersey and California). Commercial operations are established in the U.S. (California) and are expanding in Europe to support product launches. Corporate functions are centered at its global headquarters in Denmark.

Street Address:

Tuborg Boulevard 5

City:

Hellerup

State/Province:

Country:

Denmark

Ascendis Pharma's Global Presence

Redwood City, California/USA

Address: 500 Oracle Parkway, Suite 225, Redwood City, CA 94065, USA

Hub for research and early development, and U.S. commercial operations, leveraging the Bay Area's biotech ecosystem.

Palo Alto, California/USA

Address: 500 Emerson Street, Palo Alto, CA 94301, USA

Serves as a key U.S. hub, focusing on corporate operations, business development, and maintaining a presence in the San Francisco Bay Area biotech ecosystem.

Princeton, New Jersey/USA

Address: 600 College Road East, Suite 2200, Princeton, NJ 08540, USA

Centralizes U.S. clinical trial management, medical strategy, and interactions with regulatory bodies like the FDA, leveraging the region's pharmaceutical talent pool.

Heidelberg/Germany

Address: Im Neuenheimer Feld 583, D-69120 Heidelberg, Germany

Significant European R&D hub, focusing on later-stage product development, manufacturing process optimization, and research activities, benefiting from Germany's strong biotech infrastructure.

Buying Intent Signals for Ascendis Pharma

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Ascendis Pharma

As of April 2025, Ascendis Pharma' leadership includes:

Jan Mikkelsen - President & Chief Executive Officer
Scott T. Smith - Executive Vice President & Chief Financial Officer
Dr. Stina Singel - Executive Vice President, Head of Clinical Development, Operations & Biometrics
Dr. Juha Punnonen - Executive Vice President & Head of Oncology
Dr. Lene Andersen - Executive Vice President & Chief People Officer
Dr. Jesper Høiland - Executive Vice President, Global Chief Commercial Officer
Dr. Kennett Sprogøe - Executive Vice President & Head of Innovation and Research Strategy
Dr. Kim Kjøller - Executive Vice President & Head of Global Medical Affairs and Patient Safety
Joe Kelly - Executive Vice President, General Counsel

Investors of Ascendis Pharma

Ascendis Pharma has been backed by several prominent investors over the years, including:

Fidelity Management & Research Company LLC
BlackRock, Inc.
The Vanguard Group, Inc.
RA Capital Management, L.P.
Baker Bros. Advisors LP

Executive New Hires/Exits in the Last 12 Months

Hire0
Exits0

During the past 12 months, Ascendis Pharma announced several key internal promotions within its executive team in January 2024, elevating senior leaders to Executive Vice President roles to further strengthen its capabilities in clinical development, oncology, and human resources. No high-profile executive departures were publicly announced.

New Appointments:

Dr. Stina Singel, Dr. Stina Singel appointed to new role as Executive Vice President, Head of Clinical Development, Operations & Biometrics following promotion.
Dr. Juha Punnonen, Dr. Juha Punnonen appointed to new role as Executive Vice President & Head of Oncology following promotion.
Dr. Lene Andersen, Dr. Lene Andersen appointed to new role as Executive Vice President & Chief People Officer following promotion.

Technology (Tech Stack) used by Ascendis Pharma

Discover the tools Ascendis Pharma uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Ascendis Pharma Email Formats and Examples

Ascendis Pharma A/S appears to use a primary email format of [first_name_initial][last_name_initial]@ascendispharma.com for some staff, particularly senior leadership (e.g., jm@ascendispharma.com for Jan Mikkelsen). Other common formats like [first_name].[last_name]@ascendispharma.com or [first_name_initial][last_name]@ascendispharma.com may also be in use across the organization. Verification is recommended for specific contacts.

[fi][li]@ascendispharma.com

Format

es@ascendispharma.com

Example

75%

Success rate

News and media

Ascendis Pharma Investor RelationsMay 21, 2024

Ascendis Pharma A/S Announces Pricing of Upsized Public Offering of ADSs

Ascendis Pharma A/S announced the pricing of an upsized underwritten public offering of 4,347,827 American Depositary Shares ('ADSs'), each representing one ordinary share of Ascendis, at a public offering price of $115.00 per ADS....more

Ascendis Pharma Investor RelationsMay 8, 2024

Ascendis Pharma A/S Reports First Quarter 2024 Financial Results and Provides Business Update

Ascendis Pharma A/S reported financial results for the first quarter ended March 31, 2024, highlighting revenue growth from SKYTROFA and YORVIPATH, and progress in its pipeline programs....more

Ascendis Pharma Investor RelationsApril 24, 2024

Ascendis Pharma A/S Receives Positive CHMP Opinion for YORVIPATH® (Palopegteriparatide) as the First Hormone Replacement Therapy for Chronic Hypoparathyroidism in Adults

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorisation for YORVIPATH® (palopegteriparatide), a long-acting parathyroid hormone replacement therapy for adults with chronic hypoparathyroidism....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Ascendis Pharma, are just a search away.